Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Intracellular Delivery of Glutathione Peroxidase Degrader Induces Ferroptosis In Vivo
Tianli Luo, Qizhen Zheng, Leihou Shao, et al.
Angewandte Chemie International Edition (2022) Vol. 61, Iss. 39
Closed Access | Times Cited: 78

Showing 1-25 of 78 citing articles:

GPX4 in cell death, autophagy, and disease
Yangchun Xie, Rui Kang, Daniel J. Klionsky, et al.
Autophagy (2023) Vol. 19, Iss. 10, pp. 2621-2638
Open Access | Times Cited: 217
Targeting ferroptosis opens new avenues for the development of novel therapeutics
Shumin Sun, Jie Shen, Jianwei Jiang, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 216
The therapeutic potential of targeting regulated non-apoptotic cell death
Kamyar Hadian, Brent R. Stockwell
Nature Reviews Drug Discovery (2023) Vol. 22, Iss. 9, pp. 723-742
Closed Access | Times Cited: 162
Ferroptosis in cancer: From molecular mechanisms to therapeutic strategies
Qian Zhou, Yu Meng, Daishi Li, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 133
Ferroptosis Detection: From Approaches to Applications
Fantian Zeng, Sureya Nijiati, Longguang Tang, et al.
Angewandte Chemie International Edition (2023) Vol. 62, Iss. 35
Open Access | Times Cited: 112
A MOF-Based Potent Ferroptosis Inducer for Enhanced Radiotherapy of Triple Negative Breast Cancer
Lijuan Zeng, Shuaishuai Ding, Yuhua Cao, et al.
ACS Nano (2023) Vol. 17, Iss. 14, pp. 13195-13210
Closed Access | Times Cited: 82
Ferroptosis Nanomedicine: Clinical Challenges and Opportunities for Modulating Tumor Metabolic and Immunological Landscape
Huocheng Yang, Xuemei Yao, Yingqi Liu, et al.
ACS Nano (2023) Vol. 17, Iss. 16, pp. 15328-15353
Closed Access | Times Cited: 51
Ferroptosis: principles and significance in health and disease
Fangquan Chen, Rui Kang, Daolin Tang, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 44
Transformable Supramolecular Self‐Assembled Peptides for Cascade Self‐Enhanced Ferroptosis Primed Cancer Immunotherapy
He Wang, Di Jiao, Dexiang Feng, et al.
Advanced Materials (2024) Vol. 36, Iss. 21
Closed Access | Times Cited: 24
Exploiting ferroptosis vulnerabilities in cancer
Toshitaka Nakamura, Marcus Conrad
Nature Cell Biology (2024) Vol. 26, Iss. 9, pp. 1407-1419
Closed Access | Times Cited: 24
Targeting ferroptosis: Paving new roads for drug design and discovery
Yilin Gu, Yizhe Li, Jiaxing Wang, et al.
European Journal of Medicinal Chemistry (2022) Vol. 247, pp. 115015-115015
Closed Access | Times Cited: 50
Orthogonal Chemical Activation of Enzyme-Inducible CRISPR/Cas9 for Cell-Selective Genome Editing
Weiqi Cai, Ji Liu, Xianghan Chen, et al.
Journal of the American Chemical Society (2022) Vol. 144, Iss. 48, pp. 22272-22280
Closed Access | Times Cited: 42
Ferroptosis: The Entanglement between Traditional Drugs and Nanodrugs in Tumor Therapy
Kexuan Liu, Lei Huang, Shuangyan Qi, et al.
Advanced Healthcare Materials (2023) Vol. 12, Iss. 12
Closed Access | Times Cited: 37
Near-Infrared-Activatable PROTAC Nanocages for Controllable Target Protein Degradation and On-Demand Antitumor Therapy
Qi He, Liming Zhou, D.P. Yu, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 15, pp. 10458-10472
Closed Access | Times Cited: 26
Chiral CuxOS@Fe‐MOFs for Enhanced Cancer Therapy
Changlong Hao, Lu Huang, Hongyu Zhang, et al.
Advanced Functional Materials (2023) Vol. 34, Iss. 10
Closed Access | Times Cited: 24
Hybrid molecules synergistically mitigate ferroptosis and amyloid-associated toxicities in Alzheimer's disease
Dikshaa Padhi, Prayasee Baruah, Madhu Ramesh, et al.
Redox Biology (2024) Vol. 71, pp. 103119-103119
Open Access | Times Cited: 14
Targeting GPX4 in ferroptosis and cancer: chemical strategies and challenges
Jiao Liu, Daolin Tang, Rui Kang
Trends in Pharmacological Sciences (2024) Vol. 45, Iss. 8, pp. 666-670
Closed Access | Times Cited: 14
Ferroptosis-Based Therapeutic Strategies toward Precision Medicine for Cancer
Tianqi Shi, Xiaofei Chen, Huihui Ti
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 4, pp. 2238-2263
Closed Access | Times Cited: 12
ML162 derivatives incorporating a naphthoquinone unit as ferroptosis/apoptosis inducers: Design, synthesis, anti-cancer activity, and drug-resistance reversal evaluation
Furong Ma, Yulong Li, Mao-Hua Cai, et al.
European Journal of Medicinal Chemistry (2024) Vol. 270, pp. 116387-116387
Closed Access | Times Cited: 10
Cuproptosis, ferroptosis and PANoptosis in tumor immune microenvironment remodeling and immunotherapy: culprits or new hope
Xiaojie Zhang, Bufu Tang, Jinhua Luo, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 9
What influences the activity of Degrader−Antibody conjugates (DACs)
Yaolin Guo, Xiaoxue Li, Yang Xie, et al.
European Journal of Medicinal Chemistry (2024) Vol. 268, pp. 116216-116216
Closed Access | Times Cited: 8
Polycatechols inhibit ferroptosis and modulate tau liquid–liquid phase separation to mitigate Alzheimer's disease
Hariharan Moorthy, Madhu Ramesh, Dikshaa Padhi, et al.
Materials Horizons (2024) Vol. 11, Iss. 13, pp. 3082-3089
Closed Access | Times Cited: 8
Ferroptosis in Cancer Therapy: Mechanisms, Small Molecule Inducers, and Novel Approaches
YiLin Luo, Xin Yue Bai, L.J. Zhang, et al.
Drug Design Development and Therapy (2024) Vol. Volume 18, pp. 2485-2529
Open Access | Times Cited: 8
A self-amplified ferroptosis nanoagent that inhibits the tumor upstream glutathione synthesis to reverse cancer chemoresistance
Chuang Yang, Zheng Chen, Min Wei, et al.
Journal of Controlled Release (2023) Vol. 357, pp. 20-30
Closed Access | Times Cited: 20
Design and synthesis of proteolysis-targeting chimeras (PROTACs) as degraders of glutathione peroxidase 4
Mao-Hua Cai, Furong Ma, Can Hu, et al.
Bioorganic & Medicinal Chemistry (2023) Vol. 90, pp. 117352-117352
Closed Access | Times Cited: 18
Page 1 - Next Page

Scroll to top